Thymulin occupies a distinctive niche among the thymic peptides: it is the only one whose biological activity depends absolutely on a bound zinc ion, and the only thymic hormone that becomes undetectable after the thymus is removed. That makes it both a clean research probe of the zinc–immune axis and a compound whose handling has an unusual requirement. This monograph covers thymulin's identity, its zinc-dependent mechanism, the immunology evidence base, and what a COA should show.
Chemical identity and structure.
Thymulin — also called FTS, facteur thymique sérique — is a nonapeptide with the sequence Glu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn, produced exclusively by thymic epithelial cells. Its defining structural feature is that it is a metallopeptide: a single zinc ion is coordinated by the asparagine at position 9, the serine at position 4, and the N-terminal glutamic acid. The zinc is not optional decoration — it fixes the three-dimensional conformation the peptide needs to bind its receptor. Without zinc, thymulin is biologically inactive.
Mechanism of action.
Zinc-complexed thymulin binds high-affinity receptors on T-cell precursors (thymocytes) and mature T cells. Reported activities include promoting the differentiation of immature lymphocytes into functional T cells, enhancing natural-killer-cell cytotoxicity, modulating the balance between T-helper and T-suppressor subsets, and regulating cytokine output toward a more balanced pro-/anti-inflammatory profile. Several models also report anti-inflammatory and analgesic effects. Endogenous thymulin activity falls with age as the thymus involutes, which ties it to research on immunosenescence.
Research applications and the evidence base.
Thymulin is a classic tool in immunology, studied in T-cell differentiation, immunosenescence, the zinc–immune relationship, and neuroinflammation and pain models. The mechanistic and animal literature is substantial and long-standing; controlled human outcome data are limited, so claims should be framed at the mechanism-and-model level rather than as demonstrated clinical effects.
Human clinical trial data.
No human clinical trial has established administration parameters for thymulin; VialTalk does not provide community-sourced dosing.
Storage and handling.
Store lyophilized thymulin frozen (−20 °C).
Quality and COA considerations.
A meaningful COA should confirm identity by mass spectrometry against the nonapeptide mass, report purity by HPLC (≥98% is a reasonable benchmark), and — uniquely for this compound — ideally address zinc, since the apo- (zinc-free) peptide is inert; a buyer studying activity wants assurance the product is the active zinc complex. Endotoxin should be reported for injection or tissue-contact models.
Research-use note: This monograph is an educational summary of the published research literature for thymulin (FTS). Thymulin is for laboratory and research use only; the human clinical evidence is limited, and nothing here is medical advice.
